{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:14Z","timestamp":1791388994260,"version":"4.3.3"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172600"],"award-info":[{"award-number":["82172600"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This case report presents a premenopausal patient with high-risk hormone receptor (HR)-positive, HER2-low breast cancer who underwent breast-conserving surgery and axillary lymph node dissection after neoadjuvant chemotherapy. Despite postoperative radiotherapy, the patient did not adhere to endocrine therapy recommendations. Approximately five years later, metastases were identified in the liver, retroperitoneal lymph nodes, bones, and bladder. Notably, bladder metastasis, an exceptionally rare occurrence in breast cancer, was confirmed. Treatment with trastuzumab deruxtecan (T-DXd) demonstrated partial efficacy, though progression-free survival (PFS) was limited to six months. This case underscores the importance of vigilant follow-up and consideration of rare metastatic sites as breast cancer treatments evolve and improve. Bone-targeted therapies played a critical role, but the patient\u2019s short PFS suggests significant tumor heterogeneity. This report discusses a rare case of bladder metastasis originating from HR-positive, HER2-low breast cancer, emphasizing innovative treatments such as T-DXd.<\/jats:p>","DOI":"10.3389\/fonc.2025.1505354","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:23:21Z","timestamp":1749187401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Liver and bladder metastasis in a patient with HR-positive, HER2-low breast cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Lingting","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingkuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifeng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115625","article-title":"Organ-specificity of breast cancer metastasis","volume":"24","author":"Ibragimova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1046\/j.1365-2559.2000.00797.x","article-title":"Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases","volume":"36","author":"Bates","year":"2000","journal-title":"Histopathology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"LBA1001","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1001","article-title":"Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4\/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial","volume":"42","author":"Kalinsky","year":"2024","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.976947","article-title":"From women to women-hematuria during therapy for metastatic breast cancer, what to suspect and when to be alarmed; Bladder metastasis from breast cancer-our experience and a systematic literature review","volume":"12","author":"Malinaric","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-222031","article-title":"Breast cancer metastasis to the bladder: a literature review","author":"Kase","year":"2018","journal-title":"BMJ Case Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v130.6","article-title":"HER2-low heterogeneity between primary and paired recurrent\/metastatic breast cancer: Implications in treatment and prognosis","volume":"130","author":"Lin","year":"2024","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1484103","article-title":"Clinical characteristics and therapeutic direction of HER2 low-expression breast cancer","volume":"15","author":"Zhou","year":"2025","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41523-025-00741-y","article-title":"Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies","volume":"11","author":"Bar","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41523-021-00343-4","article-title":"Evolution of HER2-low expression from primary to recurrent breast cancer","volume":"7","author":"Miglietta","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07020-z","article-title":"The dynamics of HER2-low expression during breast cancer progression","volume":"201","author":"Anderson","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31583","article-title":"Comparative efficacy and safety of CDK4\/6 inhibitors combined with endocrine therapies for HR+\/HER2-breast cancer: Systematic review and network meta-analysis","volume":"10","author":"Tong","year":"2024","journal-title":"Heliyon"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz121","article-title":"Cyclin-dependent kinase 4\/6 inhibitors for the management of advanced or metastatic breast cancer in women","volume":"76","author":"Cersosimo","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0072","article-title":"Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results","volume":"22","author":"Loibl","year":"2017","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/01.sla.0000246844.25348.1b","article-title":"Is liver resection justified for patients with hepatic metastases from breast cancer","volume":"244","author":"Adam","year":"2006","journal-title":"Ann Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v9.13","article-title":"The role of surgical intervention for isolated breast cancer liver metastasis: Results of case-control study with comparison to medical treatment","volume":"9","author":"Wen","year":"2020","journal-title":"Cancer Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.soc.2020.09.003","article-title":"Surgical management of breast cancer liver metastasis","volume":"30","author":"Rahnemai-Azar","year":"2021","journal-title":"Surg Oncol Clin N Am"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091341","article-title":"Local treatment of breast cancer liver metastasis","volume":"11","author":"Bale","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"key":"B24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.21037\/atm-21-1458","article-title":"Exploring the concepts and practices of advanced breast cancer treatment: a narrative review","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1505354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:23:22Z","timestamp":1749187402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1505354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1505354"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1505354","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"article-number":"1505354"}}